Market Access -

Trending

in News
NICE recommends interim funding for GSK’s Zejula in ovarian cancer
January 15, 2021 Share
X
NICE recommends interim funding for GSK’s Zejula in ovarian cancer
https://pharmaphorum.com/news/nice-recommends-interim-funding-for-gsks-zejula-in-ovarian-cancer/
in News
EMA says AstraZeneca’s COVID-19 shot could be approved on 29 January
January 12, 2021 Share
X
EMA says AstraZeneca’s COVID-19 shot could be approved on 29 January
https://pharmaphorum.com/news/ema-says-astrazenecas-covid-19-shot-could-be-approved-on-29-january/

Latest News

Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label

Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as

X

Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label

https://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/

Moderna’s COVID-19 vaccine is third approved in UK

Moderna’s COVID-19 vaccine is third approved in UK

The UK has approved the Moderna coronavirus vaccine, hard on the heels of its go-ahead in Europe, although

X

Moderna’s COVID-19 vaccine is third approved in UK

https://pharmaphorum.com/news/modernas-covid-19-vaccine-is-third-approved-in-uk/

Unconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancer

Unconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancer

NICE has rejected Bristol Myers Squibb’s immunotherapy Opdivo as a second-line treatment for head and neck cancer in

X

Unconvinced by NHS test run, NICE rejects BMS’ Opdivo in head and neck cancer

https://pharmaphorum.com/news/unconvinced-by-nhs-test-run-nice-rejects-bms-opdivo-in-head-and-neck-cancer/

Views & analysis

2021 – UK market access prospects

2021 – UK market access prospects

With a new year comes the opportunity to think ahead for the market access landscape for the coming

X

2021 – UK market access prospects

https://pharmaphorum.com/views-analysis-market-access/2021-uk-market-access-prospects/

Why cell therapy manufacture is a team sport

Why cell therapy manufacture is a team sport

Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that

X

Why cell therapy manufacture is a team sport

https://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/

Nine for 2021: The COVID-19 legacy

Nine for 2021: The COVID-19 legacy

In the first of a two part series, IQVIA’s Sarah Rickwood covers nine key trends and events that

X

Nine for 2021: The COVID-19 legacy

https://pharmaphorum.com/views-and-analysis/nine-for-2021-the-covid-19-legacy/

Debates & Insights

Innovative contracting in Europe – a Trojan horse?

Innovative contracting in Europe – a Trojan horse?

Overview With pricing of drugs at the centre of political and social debate, the market access and pricing

X

Innovative contracting in Europe – a Trojan horse?

https://pharmaphorum.com/market-access-2/innovative-contracting-in-europe-a-trojan-horse/

Launch excellence in a disrupted world – challenges & opportunities

Launch excellence in a disrupted world – challenges & opportunities

Overview The launch environment has undergone huge changes as the pharmaceutical industry’s focus has moved from primary care

X

Launch excellence in a disrupted world – challenges & opportunities

https://pharmaphorum.com/market-access-2/launch-excellence-in-a-disrupted-world-challenges-opportunities/

Orphan medicines launch excellence: sustaining launch success

Orphan medicines launch excellence: sustaining launch success

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients

X

Orphan medicines launch excellence: sustaining launch success

https://pharmaphorum.com/market-access-2/orphan-medicines-launch-excellence-sustaining-launch-success/

Partner Content

2nd Manufacturing Assets & Facility Management in Pharma (MAFM) Summit

2nd Manufacturing Assets & Facility Management in Pharma (MAFM) Summit

Industry Led Conference on Pharma Manufacturing

X

2nd Manufacturing Assets & Facility Management in Pharma (MAFM) Summit

https://pharmaphorum.com/events/2nd-manufacturing-assets-facility-management-in-pharma-mafm-summit/

Clinical Document World | Virtual 2021

Clinical Document World | Virtual 2021

Clinical Document World will be held Jan 19-21, 2021

X

Clinical Document World | Virtual 2021

https://bit.ly/2VXedRL

Registration opens for Pre-filled Syringes & Injectable Devices Conference 2021

Registration opens for Pre-filled Syringes & Injectable Devices Conference 2021

Registration opens for Pre-filled Syringes Conference

X

Registration opens for Pre-filled Syringes & Injectable Devices Conference 2021

https://pharmaphorum.com/partner-content/registration-opens-for-pre-filled-syringes-injectable-devices-conference-2021/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com